Blueberry Therapeutics

Pharmaceuticals

Deal Type
Equity Finance

Initial Investment
May 2021

Sector
Healthcare

Fund
NPIF Maven Equity Finance

Status
Current

Based at Alderley Park, Macclesfield, Blueberry focuses on developing innovative nanomedicines for difficult to treat skin and nail infections such as onychomycosis, athlete’s foot, atopic dermatitis, topical analgesia and acne. Blueberry’s nanomedicines enable enhanced drug delivery into skin and nail for better patient outcomes, with differentiation from current products by matching or improving upon existing drug efficacy at significantly reduced doses. This also translates to improved patient safety and drug tolerability, increased compliance, and reduced cost of goods.

The funding will support the business as it embarks on the next set of clinical trials for a new topical antifungal spray for the treatment of onychomycosis using its unique nanodelivery platform technology, as well as progressing other product development lines.

Blueberry Therapeutics

We are very happy to have Maven as part of the Blueberry team as we now enter an important phase of our company development.

John Ridden, CEO at Blueberry Therapeutics

Meet the lead executive(s)

Gavin Bell
Gavin Bell

Senior Investment Manager

Subscribe for email updates

close